OBJECTIVE: To determine if metformin improves markers of inflammation, thrombosis, and intrahepatic fat contents in children with uncomplicated obesity. METHODS:Obese children with normal glucose tolerance but elevated highly sensitive C-reactive protein (hsCRP) and/or fibrinogen concentrations (>2 standard deviations) were randomized to structured diet/exercise or diet/exercise and metformin for 6 months. Blood samples, dual energy X-ray absorptiometry data, and liver magnetic resonance images were obtained. RESULTS:Forty-two of 66 recruited children (7-18 years) completed 6 months. Weight loss was modest but more pronounced in the metformin group (-4.9 +/- 1.0 kg) than in the diet/exercise group (-1.7 +/- 1.1 kg, p<0.03), whereas hsCRPand fibrinogen decreased more in the diet/exercise pubertal group. Baseline intrahepatic fat was high but decreased only in the diet/exercise (not metformin) pubertal group. CONCLUSIONS: Six months of metformin therapy improved weight loss and reduced abdominal adiposity, but did not enhance the beneficial effect of diet and exercise on markers related to inflammation, thrombosis, or hepatic fat in obese children with normal glucose tolerance.
RCT Entities:
OBJECTIVE: To determine if metformin improves markers of inflammation, thrombosis, and intrahepatic fat contents in children with uncomplicated obesity. METHODS:Obesechildren with normal glucose tolerance but elevated highly sensitive C-reactive protein (hsCRP) and/or fibrinogen concentrations (>2 standard deviations) were randomized to structured diet/exercise or diet/exercise and metformin for 6 months. Blood samples, dual energy X-ray absorptiometry data, and liver magnetic resonance images were obtained. RESULTS: Forty-two of 66 recruited children (7-18 years) completed 6 months. Weight loss was modest but more pronounced in the metformin group (-4.9 +/- 1.0 kg) than in the diet/exercise group (-1.7 +/- 1.1 kg, p<0.03), whereas hsCRP and fibrinogen decreased more in the diet/exercise pubertal group. Baseline intrahepatic fat was high but decreased only in the diet/exercise (not metformin) pubertal group. CONCLUSIONS: Six months of metformin therapy improved weight loss and reduced abdominal adiposity, but did not enhance the beneficial effect of diet and exercise on markers related to inflammation, thrombosis, or hepatic fat in obesechildren with normal glucose tolerance.
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: J J Stec; H Silbershatz; G H Tofler; T H Matheney; P Sutherland; I Lipinska; J M Massaro; P F Wilson; J E Muller; R B D'Agostino Journal: Circulation Date: 2000-10-03 Impact factor: 29.690
Authors: Silva Arslanian; Laure El Ghormli; Fida Bacha; Sonia Caprio; Robin Goland; Morey W Haymond; Lynne Levitsky; Kristen J Nadeau; Neil H White; Steven M Willi Journal: Diabetes Care Date: 2016-11-01 Impact factor: 19.112
Authors: Cheril L Clarson; Hilary K Brown; Stefanie De Jesus; Michelle Jackman; Farid H Mahmud; Harry Prapavessis; Tracy Robinson; J Kevin Shoemaker; Margaret Watson; A Justine Dowd; David J Hill Journal: Int Sch Res Notices Date: 2014-11-10